Verrica Pharmaceuticals Inc.

Contributing Author

Recent Articles by Verrica Pharmaceuticals Inc.

Jul-30	Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 VRCA GlobeNewswire
Jul-21	Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH for the Treatment of Molluscum Contagiosum in Israel VRCA GlobeNewswire
Jun-22	Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH (VP-102) for the Treatment of Common Warts VRCA GlobeNewswire
May-28	Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference VRCA GlobeNewswire
May-13	Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ VRCA GlobeNewswire
May-12	Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results VRCA GlobeNewswire
May-05	Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting VRCA +12.58% VRCA +17.74% GlobeNewswire
May-05	Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026 VRCA +12.58% GlobeNewswire
Apr-09	Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting VRCA VRCA -12.35% GlobeNewswire
Apr-06	Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference VRCA +9.32% GlobeNewswire
Mar-11	Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results VRCA GlobeNewswire
Mar-05	Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026 VRCA GlobeNewswire
Feb-23	Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference VRCA GlobeNewswire
Feb-12	Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer VRCA GlobeNewswire
Feb-09	Verrica Pharmaceuticals Announces Launch of YCANTH for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical VRCA GlobeNewswire
Jan-07	Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH (VP-102) for the Treatment of Common Warts VRCA GlobeNewswire
Nov-24	Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway VRCA +12.11% GlobeNewswire
Nov-14	Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results VRCA VRCA -5.09% GlobeNewswire
Nov-10	Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting VRCA +11.85% GlobeNewswire
Oct-20	Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH in the European Union VRCA +7.95% VRCA -9.82% GlobeNewswire
Oct-07	Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting VRCA GlobeNewswire
Sep-19	Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH (TO-208) in Japan for the Treatment of Molluscum Contagiosum VRCA +8.66% GlobeNewswire
Sep-02	Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference VRCA GlobeNewswire
Aug-12	Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results VRCA GlobeNewswire
Aug-06	Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025 VRCA +9.20% GlobeNewswire
Jul-09	Verrica Pharmaceuticals Reports Strong Growth in YCANTH Dispensed Applicator Units in 2Q 2025 VRCA GlobeNewswire
Jul-01	Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH for the Treatment of Common Warts VRCA +13.37% GlobeNewswire
May-28	Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York VRCA -5.78% GlobeNewswire
May-13	Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results VRCA +8.63% GlobeNewswire
May-07	Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025 VRCA -9.20% GlobeNewswire

Verrica Pharmaceuticals Inc.

Recent Articles by Verrica Pharmaceuticals Inc.

Upgrade your Finviz experience